Howmet Aerospace (HWM) Receives a Buy from RBC Capital
In a report released yesterday, Leonid Timashev from RBC Capital maintained a Buy rating on Howmet Aerospace, with a price target of $300.00. The company’s shares closed yesterday at $253.91.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Timashev covers the Healthcare sector, focusing on stocks such as Cytokinetics, Exelixis, and Axsome Therapeutics. According to TipRanks, Timashev has an average return of 17.0% and a 52.23% success rate on recommended stocks.
In addition to RBC Capital, Howmet Aerospace also received a Buy from TipRanks – OpenAI’s OpenAI Industrial – Machinery in a report issued today. However, yesterday, UBS maintained a Hold rating on Howmet Aerospace (NYSE: HWM).
Based on Howmet Aerospace’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.17 billion and a net profit of $372 million. In comparison, last year the company earned a revenue of $1.89 billion and had a net profit of $314 million
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HWM in relation to earlier this year. Last month, Barbara Lou Shultz, the VP & Controller of HWM sold 1,000.00 shares for a total of $260,000.00.
Read More on HWM:
Disclaimer & DisclosureReport an Issue
- Balanced Risk-Reward Keeps Howmet at Hold Despite Strong Multi-Year Growth Outlook
- Howmet Aerospace Highlights Strategy at Technology and Markets Day
- Defense Startup Anduril Rockets Toward a $60 Billion Valuation in New Round
- Howmet Aerospace Issues Senior Notes to Fund Acquisition
- Howmet Aerospace price target raised to $300 from $250 at BofA
